Glucose and Activity Tracking for Sedentary Behavior Interventions in Older Adults with Type 2 Diabetes
Official title: Glucose and Activity Tracking for Sedentary Behavior Interventions in Older People With Type 2 Diabetes (TRACK T2D)
Run by University of Minnesota · NCT07524205 · Data updated 2026-11-12
This study tests whether using a continuous glucose monitor and activity data helps people aged 55 and up with type 2 diabetes reduce sedentary time and improve glucose control.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 55 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Status | Recruiting |
| Started | May 12, 2026 |
| Main results expected | October 31, 2027 |
| Study ends | October 31, 2027 |
| Registry record updated | June 4, 2026 |
| Trial ID | NCT07524205 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are English-speaking adults 55+ with type 2 diabetes for at least 5 years who are willing to wear CGM, activPAL, and Fitbit.
✕Probably not a fit
Patients not willing or able to wear the monitoring devices or with conditions limiting physical activity may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an explanatory mixed-methods study led by the University of Minnesota that examines how older adults with long-standing type 2 diabetes integrate CGM and activity metrics into self-management. Participants will engage with CGM, activPAL, and Fitbit devices to monitor glucose and activity patterns and to guide sedentary-behavior interventions. The study will collect qualitative and quantitative data to understand feasibility, acceptability, and potential effects on sedentary behavior and glucose outcomes. Recruitment is limited to English-speaking adults aged 55 and older with at least 5 years of diagnosed T2D who are willing to wear the devices. Individuals with type 1 diabetes, dementia, and certain mobility or severe medical conditions are excluded to protect safety and data integrity.
Why it matters
Potential benefit: If successful, participants may see improved glucose control and reduced sedentary time through more informed self-management.
How similar studies have gone: Prior studies using CGM and activity data have shown promise in improving self-management, but applicability to older adults with long-standing T2D remains an area of ongoing study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 55 years and older * Self-reported T2D for ≥5 years * Speak and read English Exclusion Criteria: * Type 1 diabetes * Use of a CGM for ≥1 month in past 1 year * Not willing to use/wear the CGM, activPAL, or Fitbit * Dementia * Any of the following conditions that may impact SB: 1. Severe pulmonary disease 2. Severe osteoarthritis 3. Class III/IV heart failure 4. Require wheelchair or walker
Where it's running
-
University of Minnesota
Minneapolis, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Mary Whipple, PhD, RN, PHN, FSVM, FAHA — University of Minnesota
- Study coordinator: Mary Whipple, PhD, RN, PHN, FSVM, FAHA
- Email: sittingresearch@umn.edu
- Phone: 612-626-5823
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proliverenol for liver fat and insulin resistance in type 2 diabetes
This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes
This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.
-
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes
This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin
This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.